Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What External and Internal Drivers Are Contributing to the Growth of theExocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
A rise in diabetes cases is believed to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes, a chronic metabolic disorder, is marked by elevated blood sugar levels over an extended period due to the body’s inefficiency in producing or using insulin. EPI therapy, specifically pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption and glycemic control in diabetes and EPI patients. For instance, as per NHS England in June 2024, the number of pre-diabetes individuals identified by NHS England in 2023 stood at 3,615,330, an 18% increase from 2022’s 3,065,825. Among people under 40, the cases rose by nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Hence, the escalating number of those suffering from diabetes is boosting the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market’s growth. Growth in gastrointestinal disorders is anticipated to drive the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. These disorders affect the gastrointestinal tract, responsible for the digestion process. Here, EPI therapeutics and diagnostics come into play by addressing the enzyme deficiency causing these disorders and assisting digestion. For instance, Crohn’s and Colitis Canada reported in June 2023 that more than 322,600 Canadians, approx 0.82% of the population, were living with inflammatory bowel diseases (IBD) in 2023. As IBD prevalence continues, around 470,000 Canadians, or roughly 1.1% of the population (1 in every 91 people), are expected to be inflicted with IBD by 2035. Hence, increasing gastrointestinal diseases will, in turn, spur the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
#What Are the Key Projections for the CAGR of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market From 2025 to 2034?
There has been a significant increase in the market size of therapeutics and diagnostics for exocrine pancreatic insufficiency (EPI) in the past few years. The market, which stood at $5.69 billion in 2024, is expected to reach $6.17 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.4%. The upwards trend in the past can be linked to factors such as a rise in the incidence of underlying conditions, improvements in diagnostic technologies, advancements in pharmaceuticals, and increased accessibility to global healthcare.
In the forthcoming years, it is anticipated that the market size of exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics will witness a robust growth. The market is projected to ascend to $8.32 billion in 2029, with a compound annual growth rate (CAGR) of 7.8%. This promising growth during the forecast period can be credited to aspects such as telemedicine and remote monitoring, data analytics and ai, patient enlightenment and backing, regulatory modifications and compensation policies. The forecast period is set to see prime trends like customised treatment approaches, the emergence of novel therapies, minimally invasive diagnostics, and cooperative care models.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992
Which Upcoming Market Trends and Innovations Are Set to Influence theExocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market’s Path Forward?
Leading firms in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are employing a strategy of strategic alliances to bolster technology sharing and widen their market presence. Strategic partnerships are generally an alliance between two or more organizations, pooling their resources, skills, and energies towards shared targets. For example, Codexis, Inc., a protein engineering entity based in the US, and Nestlé Health Science, a Swiss nutrition science organization, revealed preliminary findings in February 2023 from their Phase 1 clinical research of CDX-7108 – a therapeutic under investigation for EPI treatment. This trial’s outcomes set the stage for subsequent researches that have the potential to markedly enhance EPI treatment choices for patients.
Who Are the Dominant Market Players Pushing the Boundaries of theExocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
Order Your Report Now For A Swift Delivery:
What Are the Core Segments of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, and How Do They Contribute to Growth?
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp
What Regions Are Dominating the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2025, By The Business Research Company:
Gastric Volvulus Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report
Inflammatory Bowel Disease Treatment Global Market Report 2024
Digestive Health Supplements Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/digestive-health-supplements-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
